Publications by authors named "J Suga"
Article Synopsis
- The study explores how financial stress changes over time for patients with early-stage colorectal cancer, indicating that their financial situation is dynamic.
- Conducted between May 2018 and July 2020, the research involved English-speaking adults newly diagnosed with stages I to III colorectal cancer and tracked their financial hardship through surveys at different intervals over 24 months.
- Results showed a decrease in material hardship from 57.6% to 35.0% over the study period, while cost-related care nonadherence remained stable; factors such as lower financial worry, higher education, and older age were linked to less nonadherence.
Article Synopsis
- The study investigates how variations in HLA alleles may lead to autoimmune diseases and their potential link to immune-related adverse events (irAEs), specifically thyroid issues in cancer patients.
- A case-control study included 71 cancer patients treated with immune checkpoint inhibitors, comparing the frequency of specific HLA alleles between those with and without thyroid irAEs.
- The findings show that certain HLA alleles were significantly more common in patients with thyroid irAEs, indicating a possible association between these genetic variations and the risk of developing such adverse events.
Purpose: A combination of fluorouracil, leucovorin, and oxaliplatin (FOLFOX) is the standard for adjuvant therapy of resected early-stage colon cancer (CC). Oxaliplatin leads to lasting and disabling neurotoxicity. Reserving the regimen for patients who benefit from oxaliplatin would maximize efficacy and minimize unnecessary adverse side effects.
View Article and Find Full Text PDFImportance: The longitudinal experience of patients is critical to the development of interventions to identify and reduce financial hardship.
Objective: To evaluate financial hardship over 12 months in patients with newly diagnosed colorectal cancer (CRC) undergoing curative-intent therapy.
Design, Setting, And Participants: This prospective, longitudinal cohort study was conducted between May 2018 and July 2020, with time points over 12 months.
Background: HER2 mutations are targetable alterations in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). In the SUMMIT basket study, patients with HER2-mutant MBC received neratinib monotherapy, neratinib + fulvestrant, or neratinib + fulvestrant + trastuzumab (N + F + T). We report results from 71 patients with HR+, HER2-mutant MBC, including 21 (seven in each arm) from a randomized substudy of fulvestrant versus fulvestrant + trastuzumab (F + T) versus N + F + T.
View Article and Find Full Text PDF